Skip to main content

Table 1 Survival outcomes by postoperative ctDNA status (+ vs −) based on reconstructed individual patient data

From: Prognostic value of circulating tumor DNA in operable non-small cell lung cancer: a systematic review and reconstructed individual patient-data based meta-analysis

Group (cases/ref.)

Subgroup (cases/ref.)

DFS/OS

HR

LCI

UCI

P value

Postoperative ctDNA (225/5)

OS

6.44

3.31

12.54

 < 0.001

Postoperative ctDNA (225/5)a

OS

5.59

2.84

10.98

 < 0.001

Postoperative ctDNA (225/5)b

OS

5.08

2.58

9.99

 < 0.001

Postoperative ctDNA (1051/14)

PFS

6.52

5.08

8.36

 < 0.001

Postoperative ctDNA (1051/14)a

DFS

5.88

4.51

7.67

 < 0.001

Postoperative ctDNA (1051/14)b

DFS

5.85

4.46

7.67

 < 0.001

Postoperative ctDNA (538/5)c

DFS

3.87

2.57

5.83

 < 0.001

Postoperative ctDNA by PSM (106/5)

DFS

3.96

2.19

7.16

 < 0.001

Age

 < 60 years (270/6)

DFS

8.01

4.48

14.32

 < 0.001

60–69 years (194/5)

DFS

5.28

2.97

9.37

 < 0.001

70–75 years (69/6)

DFS

7.53

2.57

22.04

0.001

 > 75 years (45/5)

DFS

2.40

0.94

6.18

0.090

Gender

Female (260/6)

DFS

6.44

3.30

12.57

 < 0.001

Male (318/6)

DFS

5.52

3.61

8.44

 < 0.001

Smoking history

With (299/6)

DFS

5.66

3.47

9.24

 < 0.001

Without (358/5)

DFS

5.62

3.69

8.55

 < 0.001

Tumor size

 ≤ 2 cm (188/3)

DFS

8.40

3.21

21.95

 < 0.001

2.1–3 cm (157/4)

DFS

7.66

3.87

15.15

 < 0.001

3.1–5 cm (133/4)

DFS

4.98

2.63

9.44

 < 0.001

 > 5 cm (35/4)

DFS

1.11

0.32

3.82

0.913

Pathological type

AD (534/10)

DFS

6.93

4.73

10.17

 < 0.001

SCC (161/10)

DFS

3.56

2.06

6.15

 < 0.001

Other (43/8)

DFS

3.04

1.26

7.36

0.022

T stage

T1 (298/7)

DFS

8.56

4.58

15.99

 < 0.001

T2 (235/7)

DFS

4.74

2.98

7.53

 < 0.001

T3&T4 (87/7)

DFS

2.16

1.09

4.28

0.043

N stage

N0 (419/8)

DFS

4.82

2.72

8.54

 < 0.001

N1 (97/7)

DFS

4.69

2.45

8.96

 < 0.001

N2 (114/8)

DFS

3.62

2.10

6.25

 < 0.001

Pathological stage

Stage I (376/9)

DFS

5.50

2.77

10.92

 < 0.001

Stage II (160/9)

DFS

4.83

2.68

8.68

 < 0.001

Stage III (153/9)

DFS

2.80

1.79

4.37

 < 0.001

ACT

With (310/10)

DFS

4.06

2.70

6.09

 < 0.001

Without (341/8)

DFS

10.48

6.65

16.52

 < 0.001

  1. ACT adjuvant chemotherapy, AD adenocarcinoma, HR hazard ratio, LCI lower level of 95% confidential interval, Other other types of NSCLC, OS overall survival, DFS disease-free survival, PSM propensity score matching, SCC squamous cell carcinoma, UCI upper level of 95% confidential interval
  2. aThe HR (95% CI) was calculated based on Cox regression with shared frailty model
  3. bThe HR (95% CI) was calculated based on a stratified Cox regression model
  4. cThe HR (95% CI) was calculated based on a multivariate Cox regression model including age, gender, smoke, tumor size, pathological type, T stage, N stage, and pathological stage
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us